Results 211 to 220 of about 144,800 (349)

Approaches to preventing opioid-related harms in US higher education: A PRISMA-guided scoping review. [PDF]

J Am Coll Health
Freibott CE, Major E, Vest N, Stein MD, Lipson SK.   +4 more
europepmc   +1 more source

Transmucosal fentanyl-related opioid use disorder in a cancer survivor [PDF]

Salim Mezaache, Christophe Cutarella, Élisabeth Frauger, Joëlle Micallef   +3 more
openalex   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Pain and treatment outcomes after initiating methadone vs buprenorphine among medicare patients with opioid use disorder and comorbid chronic pain: A target trial emulation. [PDF]

PLoS Med
Wei YJ, Winterstein AG, Fillingim RB, Schmidt S, Schmidt S.   +4 more
europepmc   +1 more source

Association Between Opioid Use and Emergency Department Visits for Spine-Related Disorders

Chijioke Okeke, Godwin Okoye, J. Douglas Thornton   +2 more
openalex   +2 more sources

Impact of opioid dose escalation on the development of substance use disorders, accidents, self‐inflicted injuries, opioid overdoses and alcohol and non‐opioid drug‐related overdoses: a retrospective cohort study

, 2020
Corey J. Hayes, Erin E. Krebs, Teresa J. Hudson, Joshua D. Brown, Chenghui Li, Bradley C. Martin   +5 more
openalex   +2 more sources

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Low-Dose Naltrexone in Chronic Pain Management: Mechanisms, Evidence, and Clinical Implications. [PDF]

J Pers Med
McKenzie A, Bittar T, Dombrower R, Raman D, Hussain H, Theeraphapphong N, McKenzie SM, Abd-Elsayed A.   +7 more
europepmc   +1 more source

Analgesic opioids in pregnancy and placental malperfusion-related disorders: a population-based cohort study [PDF]

Jonathan Brett, Claudia Bruno, Bianca Varney, Alys Havard, Antonia Shand, Krista F. Huybrechts, Helga Zoëga   +6 more
openalex   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source